pharmaceuticals [12:<45 kg who received rifapentine 450 mg and in those weighing 45 kg who received 600 mg were similar to those reported in adults. 1 Stability Storage Oral Tablets 25 C (may be exposed to 15 30 C); protect from excessive heat and humidity. 1 Actions and Spectrum A cyclopentyl rifamycin structurally and pharmacologically similar to other rifamycins (rifampin, rifabutin). 1 2 3 5 14 Usually bactericidal in action. 1 Inhibits DNA-dependent RNA polymerases in susceptible Mycobacterium tuberculosis . 1 Both rifapentine and its major metabolite have antimicrobial activity. 1 Mycobacterium : Active in vitro and in clinical infections against M. tuberculosis . 1 2 3 5 19 20 Has some activity against M. avium complex (MAC); 5 19 clinical relevance unclear. 1 Gram-negative bacteria: Active in vitro against Brucella , 13 Legionella , 7 Neisseria , 20 Haemophilus influenza , 20 Bordetella pertussis , and B. parapertussis . 6 Gram-positive bacteria: Active in vitro against streptococci, 20 staphylococci, 20 Corynebacterium pseudodiphtheriticum , Arcanobacterium haemolyticum (formerly Corynebacterium haemolyticum ), A. pyogenes , Listeria , Turicella otitidis , Brevibacterium , and Oerskovia . 8 Natural and acquired resistance to rifapentine reported in vitro and in vivo in strains of M. tuberculosis . 1 3 4 Cross-resistance occurs between rifapentine and other rifamycins (rifampin, rifabutin). 1 3 4 14 M. tuberculosis resistant to rifampin usually are resistant to both rifabutin and rifapentine. 14 Cross-resistance does not appear to occur between rifapentine and other antituberculosis agents (e.g., isoniazid, streptomycin). 1 Advice to Patients Advise patients that poor compliance with antituberculosis regimens can result in treatment failure and development of drug-resistant TB, which can be life-threatening and lead to other serious health risks. 1 14 Importance of completing full course of therapy; importance of not missing any doses. 1 Advise patients likely to experience nausea, vomiting, or GI upset to take rifapentine with food. 1 Advise patient that rifapentine may impart a red-orange color to urine, sweat, sputum, tears, and breast milk. 1 Soft contact lenses and dentures may become permanently stained. 1 Importance of informing clinicians if fever, loss of appetite, malaise, nausea, vomiting, darkened urine, yellow discoloration of the skin or eyes, or pain or swelling of the joints occurs. 1 Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs, as well as any concomitant illnesses. 1 Advise patient that reliability of oral or other systemic hormonal contraceptives may be affected; alternative contraceptives should be considered. 1 Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. 1 Importance of informing patients of other important precautionary information. 1 (See Cautions.) Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. Rifapentine Routes Dosage Forms Strengths Brand Names Manufacturer Oral Tablets, film-coated 150 mg Priftin (with propylene glycol) Sanofi-Aventis AHFS DI Essentials. Copyright 2017, Selected Revisions February 1, 2008. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. References 1. Sanofi-Aventis. Priftin (rifapentine) 150 mg tablets prescribing information. Bridgewater, NJ; 2006 Dec. 2. Mor N, Simon B, Mezo N et al. Comparison of activities of rifapentine and rifampin against Myocobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother . 1995; 39:2073-7. [PubMed 8540718] 3. Moghazeh SL, Pan XI, Arain T et al. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with a known rpoB mutations. Antimicrobial Agents cehmother . 1996; 40: 2655-7. 4. Tam CM, Chan SL, Lam CW et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Am J Respir Crit Care Med . 1998; 157: 1726-33. [PubMed 9620898] 5. Heifets LB, Lindholm-Levy J, Flory MA. Bactericidal activity in vitro of various rifamycins against Myocbacterium avium and Mycobacterium tuberculosis . Am Rev Respir Dise . 1990; 141:626-30. 6. Hoppe JE, Bryskier A. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycinA, and roxithromycin), and two ansamycins (rifampin and rifapentine). Antimicrob Agents Chemother . 1998; 42:965-6. [PubMed 9559823] 7. Schulin T, Wennersten CB, Ferraro MJ et al. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother . 1998; 42:1520-3. [PubMed 9624509] 8. Soriano F, Fernandez-Roblas R, Calvo R et al. In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials. Antimicrob Agents Chemother . 1998; 42:1028-33. [PubMed 9593121] 9. Keung ACF, Eller MG, Weir SJ. Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction. J Clin Pharmacol . 1998; 38: 517-24. 10. Keung ACF, Miller TD, Green VI et al. Bioavailability (BA) and food effects study of rifapentine in healthy adults. Pharm Res . 1995; 12(suppl):S419. 11. Reith K, Keung A, Toren PC et al. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab Dispos . 1998; 26:732-8. [PubMed 9698286] 12. Durand DV, Hampden C, Boobis AR et al. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. Br J Clin Pharmac . 1986; 21:1-7. 13. Garcia-Rodriguez JA, Munoz-Bellido JL, Fresnadillo MJ et al. In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrobial Agents and Chemother . 1993; 37:911-3. 14. Centers for Disease Control and Prevention. Treatment of tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Recomm Rep . 2003; 52(RR-11):1-77. 15. US Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep . 1993; 42(RR-7):1-8. 16. Bolan G, Laurie RE, Broome CV. Red man syndrome: inadvertent administration of an excessive dose of rifampin to children in a day-care center. Pediatrics . 1986; 77:633-5. [PubMed 3486402] 17. Hoechst Marion Roussel. Rifadin (rifampin capsules) and Rifadin I.V. (rifampin for injection) prescribing information (dated 1995 May). In: Physicians desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:1276-8. 18. Centers for Disease Control. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep . 1996; 45:921-5. [PubMed 8927017] 19. Jarvis B, Lamb HM. Rifapentine. Drugs . 1998; 56:607-16. [PubMed 9806107] 20. Felmingham D, Robbins MJ, Clark S et al. The in vitro activity of rifampicin and rifapentine against recent clinical bacterial isolates. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: American Society for Microbiology. 1997:152. Abstract No. F-35. 21. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep . 1998; 47(RR-20):1-58. 22. Tam CM. Rifapentine: a viewpoint. Drugs . 1998; 56:617. 23. Chaulet P. Rifapentine: a viewpoint. Drugs . 1998; 56:617. 24. Johnson S, Gerding DN. Clostridium difficile -associated diarrhea. Clin Infect Dis . 1998; 26:1027-36. [PubMed 9597221] 25. Gerding DN, Johnson S, Peterson LR et al for the Society for Healthcare Epidemiology of American. Position paper on Clostridium difficile -associated diarrhea and colitis. Infect Control Hosp Epidemiol . 1995; 16:459-77. [PubMed 7594392] 26. Fekety R for the American College of Gastroenterology Practice Parameters Committee. Guidelines for the diagnosis and management of Clostridium difficile -associated diarrhea and colitis. Am J Gastroenterol . 1997; 92:739-50 (IDIS 386628) [PubMed 9149180] 27. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile -associated disease. Am J Health-Syst Pharm . 1998; 55:1407-11. [PubMed 9659970] 28. Wilcox MH. Treatment of Clostridium difficile infection. J Antimicrob Chemother . 1998; 41(Suppl C):41-6. [PubMed 9630373] 29. Food and Drug Administration. Priftin (rifapentine) tablets [October 20, 2000: Aventis]. MedWatch drug labeling changes. Rockville, MD; October 2000. From FDA website (). 31. Aventis Pharmaceuticals, Kansas City, MO: Personal communication. a. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (December 1, 2007). From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website (). b. Genentech. Tarceva (erlotinib) tablets prescribing information. South San Francisco, CA; 2007 Mar. Next Interactions Print this page Add to My Med List More about rifapentine Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Interactions Support Group En Español 0 Reviews Add your own review/rating Drug class: rifamycin derivatives Consumer resources Rifapentine Rifapentine (Advanced Reading) Professional resources Rifapentine (Wolters Kluwer) Other brands: Priftin Related treatment guides Tuberculosis, Active Tuberculosis, Latent> ]} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class Rifamycin derivatives Related Drugs Tuberculosis, Latent rifampin , isoniazid , pyrazinamide , Rifadin , Nydrazid , Rimactane , Priftin , More... Tuberculosis, Active ciprofloxacin , Levaquin , levofloxacin , rifampin , moxifloxacin , Avelox , isoniazid , ethambutol , amikacin , gatifloxacin , More... Rifapentine Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first!} } that provide
sound asleep Rifapentine beginners
EmoticonEmoticon